Palo Alto, CA, August 22, 2016 – enlightenbio LLC, today announced the publication of its NGS Data Analysis & Interpretation Ecosystem Analysis Report. This new report details an extensive ecosystem analysis of 25 commercial companies in the NGS data analysis and interpretation space, market trends, unmet needs and challenges. The report is unique, in that it is not a predictive market research report, but rather builds on data gathered from many end-user interviews combined with an extensive ecosystem analysis.
This comparative ecosystem analysis of key commercial data analysis and interpretation tool providers reveals a range of capabilities that uniquely address both secondary and tertiary sequence data analysis needs. At first glance, the value propositions and communication of capabilities may seem overlapping or similar. However, a deeper analysis clearly uncovers substantial differences in the product characteristics related to analysis and interpretation, data management, data sharing and collaboration, reporting of findings, compliance and security mechanisms, and type of content made available for meaningful knowledge extraction.
While this report does not intend to provide direct recommendations to end-users for specific product selection, the deep-dive evaluation is meant to be an insightful review to help researchers and commercial entities choose the best partner for success.
For a limited time only, apply Promo Code FIRST10ECO and get 10% off when purchasing the report – valid until September 30, 2016.
Download Table of Contents to learn more about the report specifics.
Report Content
The advancements in high-throughput sequencing demand powerful, yet user-friendly bioinformatics solutions to analyze and extract meaningful knowledge from the generated sequence data. In line with this demand, the sequence data analysis and interpretation space is rich with commercial bioinformatics and/or platform solutions that provide different analysis, interpretation, and reporting solutions, and is paralleled by the ever-growing open source tools space. Commercial solutions provide a multitude of bioinformatics offerings as stand-alone packages. They each differ in the capabilities offered, the user-friendliness they provide, the product(s) cost, and the target audience. This creates a challenging and sometimes bewildering environment for the end-users faced with selecting the right offering for their specific analysis needs. Accordingly, the commercial entities in turn need to clearly communicate their competitive advantage to customers to be among the winners in this field.
A set of 25 commercial companies was analyzed revealing top players who are strong in different areas of data analysis and interpretation: DNAnexus and Seven Bridges Genomics have emerged as open and flexible platforms for data analysis, while Bluebee, Genalice, and Edico Genome, as alternatives, enable fast DNA processing. On the data interpretation side, notable players are Cartagenia (Agilent), Congenica, Ingenuity (Qiagen), Omicia, Station X, Tute Genomics, and WuXi NextCODE (WuXi AppTec). Content is clearly king on the interpretation side, and tertiary companies with rich content are highly valued: it is therefore not surprising to see Ingenuity with its manually curated content receiving high marks, or Cartagenia and Omicia with the additional phenotype content being highlighted as value providers. End-user interviewees repeatedly pointed out the challenges associated with the complexity of data analysis that favors complete and integrated solutions that include secondary, tertiary and reporting capabilities. This is particularly relevant for organizations that have a range of users at different computer sophistication levels. Tute Genomics is a company that was mentioned favorably supporting the entire workflow from data analysis to interpretation, and findings reporting.
In summary, this detailed report comprises a deep ecosystem level analysis of a major set of key commercial software and platform providers (N=25) in the secondary and tertiary NGS analysis space, to understand product focus, strategy to address end-user needs, and company momentum (incl. funding situation, number of employees, and more):
- Advaita, Appistry, BaseSpace (Illumina), Bina Technologies (Roche), Bluebee, Cartagenia (Agilent), CLC Bio (Qiagen), Congenica, DNAnexus, DNASTAR, Edico Genome, Genalice, Genestack, Genomatix, Genospace, Golden Helix, Ingenuity Systems (Qiagen), Partek, Omicia, Seven Bridges Genomics, Softgenetics, SolveBio, Station X, Tute Genomics, and WuXi NextCODE (WuXi AppTec).
We are very excited about this major report release that represents a significant milestone for us in our mission to bring up-to-date, concise information with translatable value to our customer community. This report is a wise and impactful investment that will help guide significant strategic decisions, avoid potentially costly mistakes for customers, and provide valuable insight to software and platform providers looking to address unmet user and stakeholder needs.
For more information contact info@enlightenbio.com or visit our website, enlightenbio.com.
